SCHEMBL5664149

SCHEMBL5664149

CCCN(C)C(=O)C(N)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ TACR1 P25103 2/20 0.41
▸ AOC3 Q16853 3/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ CNR2 P34972 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CRHBP P24387 1/20 0.38
▸ CRHR2 Q13324 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HRH1 P35367 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5004390 0.90 KDM4E (0.46) KDM4EATMTACR1CNR2GAA
SCHEMBL14102623 0.90 KDM4E (0.46) KDM4EATMTACR1CNR2GAA
SCHEMBL5664359 0.89 KDM4E (0.44) KDM4EATMTACR1GAACYP1A2
Hydrochloric Acid SCHEMBL4940491 0.89 KDM4E (0.44) KDM4EATMTACR1CNR2GAA
Hydrochloric Acid SCHEMBL4940483 0.89 KDM4E (0.44) KDM4EATMTACR1CNR2GAA
SCHEMBL2746465 0.87 KDM4E (0.48) KDM4EATMTACR1AOC3L3MBTL1
SCHEMBL4986798 0.86 SMN1; SMN2 (0.44) KDM4EATMAOC3TDP1GAA
SCHEMBL4984176 0.85 TP53 (0.49) L3MBTL1TDP1TP53GAALMNA
SCHEMBL27734471 0.84 TACR1 (0.51) KDM4EATMTACR1AOC3MEN1
SCHEMBL5664992 0.82 SMN1; SMN2 (0.48) L3MBTL1TDP1TP53GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040132745-A1 Microsomal triglyceride transfer protein inhibitor PFIZER INC 2004-07-08 — — US claimed
EP-1716137-A1 SUBSTITUTED QUINOLINE COMPOUNDS Pfizer Products Incorporated (US) 2006-11-02 — — EP disclosed
EP-1578725-A1 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS Pfizer Products Inc. (US) 2005-09-28 — — EP disclosed
WO-2005080373-A1 SUBSTITUTED QUINOLINE COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-09-01 — — WO disclosed
WO-2004056777-A1 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS PFIZER PRODUCTS INC. (US) 2004-07-08 — — WO disclosed
US-20040132745-A1 Microsomal triglyceride transfer protein inhibitor PFIZER INC 2004-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132745-A1 Microsomal triglyceride transfer protein inhibitor MTTP, CETP, APOB KDM4E 3437/4885ATM 2710/4885TACR1 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback